<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas - Lecavalier-Barsoum, M - 2014 | Cochrane Library</title> <meta content="Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas - Lecavalier-Barsoum, M - 2014 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007104.pub2/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas - Lecavalier-Barsoum, M - 2014 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007104.pub2/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007104.pub2" name="dc.identifier" scheme="DOI"/> <meta content="Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas" name="citation_title"/> <meta content="Magali Lecavalier-Barsoum" name="citation_author"/> <meta content="McGill University Health Centre" name="citation_author_institution"/> <meta content="Harvey Quon" name="citation_author"/> <meta content="CancerCare Manitoba" name="citation_author_institution"/> <meta content="Bassam Abdulkarim" name="citation_author"/> <meta content="Montreal General Hospital" name="citation_author_institution"/> <meta content="bassam.abdulkarim@mcgill.ca" name="citation_author_email"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="5" name="citation_issue"/> <meta content="10.1002/14651858.CD007104.pub2" name="citation_doi"/> <meta content="2014" name="citation_date"/> <meta content="2014/05/15" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007104.pub2/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007104.pub2/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007104.pub2/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Astrocytoma [*drug therapy, *radiotherapy, surgery]; Brain Neoplasms [*drug therapy, *radiotherapy, surgery]; Chemotherapy, Adjuvant; Oligodendroglioma [*drug therapy, *radiotherapy, surgery]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007104.pub2&amp;doi=10.1002/14651858.CD007104.pub2&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="dLyXbLct";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007104\x2epub2\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007104\x2epub2\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ms","fa"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007104.pub2",title:"Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas",firstPublishedDate:"May 15, 2014 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007104.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007104.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007104.pub2/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007104.pub2/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007104.pub2%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007104.PUB2" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007104.pub2/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007104.PUB2" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007104.pub2/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007104.pub2/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>1480 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007104.pub2" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full#CD007104-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full#CD007104-sec-0059"> Authors' conclusions </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full#CD007104-sec-0008"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full#CD007104-sec-0012"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full#CD007104-sec-0013"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full#CD007104-sec-0034"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full#CD007104-sec-0055"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/appendices#CD007104-sec-0063"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/references#characteristicStudies"> Characteristics of studies </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2014 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/information#CD007104-cr-0004">Magali Lecavalier-Barsoum</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/information#CD007104-cr-0005">Harvey Quon</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007104.pub2/information#CD007104-cr-0006"><i class="icon corresponding-author fa fa-envelope"></i>Bassam Abdulkarim</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/information/en#CD007104-sec-0070">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 15 May 2014 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007104.pub2">https://doi.org/10.1002/14651858.CD007104.pub2</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007104-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007104-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007104-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007104-abs-0006">فارسی</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007104-abs-0001" lang="en"> <section id="CD007104-sec-0001"> <h3 class="title" id="CD007104-sec-0001">Background</h3> <p>Standard care of adjuvant treatment for anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas (AOA) is not yet well defined. The benefit of adjuvant chemotherapy and radiotherapy (RT), given as single modalities or sequentially, is still unclear. Furthermore, insight into the predictive and prognostic impact of various biomarkers is surging. </p> </section> <section id="CD007104-sec-0002"> <h3 class="title" id="CD007104-sec-0002">Objectives</h3> <p>To compare postoperative sequential RT and chemotherapy to RT alone in adults with newly diagnosed AO or mixed AOA. To evaluate the predictive and prognostic impact of the following biomarkers: codeletion of chromosomes 1p and 19q, O<sup>6</sup>‐methylguanine‐DNA methyltransferase (MGMT) promotor methylation and isocitrate dehydrogenase (IDH)‐1 and ‐2 mutations. </p> </section> <section id="CD007104-sec-0003"> <h3 class="title" id="CD007104-sec-0003">Search methods</h3> <p>We searched the Cochrane Central Register for Controlled Trials (CENTRAL, Issue 1, 2014), MEDLINE (2006 to March week 2, 2014) and EMBASE (2006 to week 11, 2014). We scanned reference lists from relevant studies for any additional articles. </p> </section> <section id="CD007104-sec-0004"> <h3 class="title" id="CD007104-sec-0004">Selection criteria</h3> <p>We included randomized controlled trials (RCTs) of adults with AO, AOA or anaplastic astrocytoma (AA) comparing adjuvant treatment of chemotherapy, RT, or sequential chemotherapy and RT. We excluded no specific chemotherapy regimens. </p> </section> <section id="CD007104-sec-0005"> <h3 class="title" id="CD007104-sec-0005">Data collection and analysis</h3> <p>We critically appraised and extracted data from relevant studies. Based on the differences in participant selection with respect to the definition of AO (two versus three high‐risk anaplastic features), the inclusion of AA and sequence of treatment (RT and chemotherapy), we could not consider the results from the three RCTs for meta‐analysis. </p> </section> <section id="CD007104-sec-0006"> <h3 class="title" id="CD007104-sec-0006">Main results</h3> <p>Three RCTs, with 931 participants, tested different neoadjuvant treatments: RT alone; sequential RT and procarbazine, lomustine and vincristine (PCV) chemotherapy; PCV chemotherapy alone; and temozolomide chemotherapy alone. None of the studies blinded participants or personnel, and, therefore, are considered at high risk of performance and detection bias. The studies were otherwise at low risk of bias. One study, the European Organisation for Research and Treatment of Cancer (EORTC) trial, demonstrated a statistically significant overall survival (OS) benefit for RT plus PCV, with a median OS of 3.5 years compared with 2.6 years in the RT alone arm (P value = 0.018). This result was reported 10 years after the conclusion of the enrolment, and was not apparent in the original 2008 Cochrane review. Furthermore, with retrospective evaluation of biomarkers, codeletion of complete chromosome arms 1p and 19q and IDH‐1 or ‐2 mutation were independent prognostic factors for OS in two of the RCTs (Radiation Therapy Oncology Group (RTOG) and EORTC), and were predictive for OS in one trial (RTOG). The third trial (NOA‐04) evaluated these biomarkers prospectively and found them prognostic for progression‐free survival. </p> </section> <section id="CD007104-sec-0007"> <h3 class="title" id="CD007104-sec-0007">Authors' conclusions</h3> <p>Early PCV, either before or after RT, appears to improve OS of participants with AO or AOA. Use of biomarkers including codeletion of chromosomes 1p and 19q with or without IDH‐1 or ‐2 mutation identify a subset of people with increased sensitivity to combined PCV and RT. The important role of biomarkers was supported in all of the RCTs examined, and prospective evaluation should be undertaken in future studies. However, PCV was associated with significant grade 3 and 4 toxicities, and whether temozolomide can be substituted for this remains unclear. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007104-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007104-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007104-abs-0005">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007104-abs-0007">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007104-abs-0003">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007104-abs-0002" lang="en"> <h3>Does giving chemotherapy, radiotherapy or both improve survival in people with rare (anaplastic oligodendrogliomas and oligoastrocytomas) brain tumours? </h3> <p><b>Background</b> </p> <p>Traditionally, the standard of care for people with rare anaplastic oligodendrogliomas and anaplastic oligoastrocytomas (brain tumours) has been surgery followed by radiotherapy. However, the benefit of adjuvant (post‐surgery) chemotherapy and radiotherapy is still unclear. In addition, the value of chromosome markers is also under investigation. </p> <p><b>Study characteristics</b> </p> <p>We searched the scientific literature up to March 2014 for studies of adults over 18 years of age with a diagnosis of anaplastic oligodendrogliomas, anaplastic oligoastrocytomas or anaplastic astrocytomas. After surgery, the participants had to have received radiotherapy alone, chemotherapy alone or radiotherapy plus chemotherapy. In the first review on this topic in 2009, we found two trials to include. In this update, we identified another trial for inclusion, and updates from the two previously included trials were taken into consideration. </p> <p><b>Key results</b> </p> <p>Three randomized controlled trials, which included 931 participants, assessed the role of chemotherapy alone or in addition to radiotherapy, or radiotherapy alone. One study was able to demonstrate a significant survival benefit for the addition of chemotherapy to radiotherapy after surgery, compared with radiotherapy alone. In addition, during examination of these brain tumour biopsy specimens, they found specific chromosome deletions and mutations in two studies, which helped to identify a group of participants with better survival outcomes. Furthermore, in one study, these specific chromosome deletions and mutations predicted which group of participants derived benefit from the addition of chemotherapy to radiotherapy after surgery. </p> <p><b>Quality of the evidence</b> </p> <p>Evidence for giving radiotherapy and chemotherapy was of good quality, but sparse.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007104-sec-0059" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007104-sec-0059"></div> <h3 class="title" id="CD007104-sec-0060">Implications for practice</h3> <section id="CD007104-sec-0060"> <p>Early procarbazine, lomustine and vincristine (PCV), either before or after radiotherapy (RT), appears to improve overall survival (OS) of participants with codeleted or isocitrate dehydrogenase (IDH)‐1 or ‐2 (or both) mutated anaplastic oligodendrogliomas (AO) or anaplastic oligoastrocytomas (AOA). However, PCV is associated with significant grade 3 and 4 toxicities, and whether temozolomide can be substituted for this remains unclear. For the moment, there is no robust evidence that temozolomide has similar beneficial effect as PCV in AO and AOA, and the ongoing trials will hopefully clarify this issue. </p> <p>Codeletion of chromosome 1p and 19q and mutation in IDH‐1 or ‐2 are strong prognostic factors for progression‐free survival (PFS) and OS and there is evidence to support the value of these biomarkers in predicting response to the addition of chemotherapy. Therefore, biomarker profiles should be included in the next World Health Organization (WHO) AO tumour subclassification. The international trials, CODEL and CATNON, will define the best sequence of combined modality. </p> </section> <h3 class="title" id="CD007104-sec-0061">Implications for research</h3> <section id="CD007104-sec-0061"> <p>Developing future biomarkers for response, as well as molecular‐targeted therapies, should be the focus of future studies in order to improve efficacy and to minimize long‐term toxicities of conventional cytotoxic therapies. </p> </section> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007104-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007104-sec-0008"></div> <p>Oligodendroglial tumours are primary brain tumours representing 1.8% of primary central nervous system (CNS) tumours and 6.2% of all CNS gliomas (<a href="./references#CD007104-bbs2-0009" title="Central Brain Tumor Registry of the United States. Primary brain tumors in the United States statistical report, 2005-2009. Neuro-oncology2009;14 Suppl 5:v1-49.">CBTRUS 2009</a>). Since the early 1990s, knowledge gained has been prolific with regards to these tumours. Interest was first hastened by demonstration of chemosensitivity of oligodendroglial tumours (<a href="./references#CD007104-bbs2-0006" title="CairncrossG , MacdonaldD , LudwinS , LeeD , CascinoT , BucknerJ , et al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology1994;12(10):2013-21.">Cairncross 1994</a>). The identification of predictive and prognostic markers, such as codeletion of chromosomes 1p and 19q, and isocitrate dehydrogenase (IDH)‐1 and ‐2, have contributed significantly to the promotion of more biological research (<a href="./references#CD007104-bbs2-0007" title="CairncrossJG , UekiK , ZlatescuMC , LisleDK , FinkelsteinDM , HammondRR , et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. Journal of the National Cancer Institute1998;90(19):1473-9.">Cairncross 1998</a>; <a href="./references#CD007104-bbs2-0022" title="SmithJS , PerryA , BorellTJ , LeeHK , O'FallonJ , HosekSM , et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. Journal of Clinical Oncology2000;18(3):636-45.">Smith 2000</a>; <a href="./references#CD007104-bbs2-0025" title="vanden BentMJ , LooijengaLH , LangenbergK , DinjensW , GravelandW , UytdewilligenL , et al. Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer2003;97:1276-84.">van den Bent 2003</a>), and have advanced our knowledge in the management of these tumours. </p> <section id="CD007104-sec-0009"> <h3 class="title" id="CD007104-sec-0009">Previous review on anaplastic oligodendrogliomas and anaplastic oligoastrocytomas</h3> <p>We published a systematic review focusing on the role of adjuvant chemotherapy in addition to radiotherapy (RT) in the treatment of anaplastic oligodendrogliomas (AO) and anaplastic oligoastrocytomas (AOA) in 2008 (<a href="./references#CD007104-bbs2-0028" title="QuonH , AbdulkarimB . Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD007104]">Quon 2008</a>). This first review concluded that early procarbazine, lomustine and vincristine (PCV) chemotherapy in addition to standard treatment of surgery and RT improved progression‐free survival (PFS), but did not improve overall survival (OS) in participants with AO and AOA. It also supported the idea that this increase in PFS was at the cost of increased toxicity. In addition, clear conclusions on the predictive value of codeletion of chromosomes 1p and 19q were not made because of lack of correlation in studies. </p> </section> <section id="CD007104-sec-0010"> <h3 class="title" id="CD007104-sec-0010">New molecular markers based on randomized controlled trials updates</h3> <p>Since this first systematic review, significant developments in predictive and prognostic markers for AO and AOA have been made. IDH‐1 and ‐2 gene mutations have been recognized as important markers for glial tumours. Identified after sequencing of the genome of glioblastomas (GBM) in 2008 (<a href="./references#CD007104-bbs2-0004" title="BalssJ , MeyerJ , MuellerW , KorshunovA , HartmannC , vonDeimlingA . Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica2008;116(6):597-602.">Balss 2008</a>; <a href="./references#CD007104-bbs2-0010" title="HartmannC , MeyerJ , BalssJ , CapperD , MuellerW , ChristiansA , et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica2009;118:469-74.">Hartmann 2009</a>; <a href="./references#CD007104-bbs2-0021" title="ParsonsDW , JonesS , ZhangX , LinJC , LearyRJ , AngenendtP , et al. An integrated genomic analysis of human glioblastoma multiforme. Science2008;321:1807-12.">Parsons 2008</a>; <a href="./references#CD007104-bbs2-0027" title="YanH , ParsonsDW , JinG , McLendonR , RasheedBA , YuanW , et al. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine2009;360:765-73.">Yan 2009</a>), they were shown to be present in 55% to 80% of oligodendrogliomas and astrocytomas World Health Organization (WHO) grades II and III. IDH‐1 and ‐2 mutations are also present in 50% to 100% of secondary GBM (<a href="./references#CD007104-bbs2-0004" title="BalssJ , MeyerJ , MuellerW , KorshunovA , HartmannC , vonDeimlingA . Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica2008;116(6):597-602.">Balss 2008</a>; <a href="./references#CD007104-bbs2-0012" title="IchimuraK , PearsonDM , KocialkowskiS , BäcklundLM , ChanR , JonesDT , et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology2009;11:341-7.">Ichimura 2009</a>; <a href="./references#CD007104-bbs2-0013" title="KloosterhofNK , BraltenLB , DubbinkHJ , FrenchPJ , vanden BentMJ . Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?The lancet oncology2011;12:83-91.">Kloosterhof 2011</a>; <a href="./references#CD007104-bbs2-0023" title="SonodaY , KumabeT , NakamuraT , KanamoriM , YamashitaY , SuzukiH , et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Science2009;100:1996-8.">Sonoda 2009</a>; <a href="./references#CD007104-bbs2-0026" title="WatanabeT , NobusawaS , KleihuesP , OhgakiH . IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. American Journal of Pathology2009;174:1149-53.">Watanabe 2009</a>; <a href="./references#CD007104-bbs2-0027" title="YanH , ParsonsDW , JinG , McLendonR , RasheedBA , YuanW , et al. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine2009;360:765-73.">Yan 2009</a>). GBM are classified as secondary when they arise from low‐grade diffuse astrocytomas or anaplastic astrocytomas (AA), as compared with primary GBM that develop rapidly de novo, without clinical or histological evidence of a less malignant precursor lesion. In addition, IDH‐1 and ‐2 mutations are thought to be initiating events in these glial tumour subtypes (<a href="./references#CD007104-bbs2-0023" title="SonodaY , KumabeT , NakamuraT , KanamoriM , YamashitaY , SuzukiH , et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Science2009;100:1996-8.">Sonoda 2009</a>; <a href="./references#CD007104-bbs2-0026" title="WatanabeT , NobusawaS , KleihuesP , OhgakiH . IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. American Journal of Pathology2009;174:1149-53.">Watanabe 2009</a>; <a href="./references#CD007104-bbs2-0027" title="YanH , ParsonsDW , JinG , McLendonR , RasheedBA , YuanW , et al. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine2009;360:765-73.">Yan 2009</a>). Interestingly, they are rare in primary GBM, as they are found in only 3% to 12% of them (<a href="./references#CD007104-bbs2-0004" title="BalssJ , MeyerJ , MuellerW , KorshunovA , HartmannC , vonDeimlingA . Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica2008;116(6):597-602.">Balss 2008</a>; <a href="./references#CD007104-bbs2-0010" title="HartmannC , MeyerJ , BalssJ , CapperD , MuellerW , ChristiansA , et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathologica2009;118:469-74.">Hartmann 2009</a>; <a href="./references#CD007104-bbs2-0012" title="IchimuraK , PearsonDM , KocialkowskiS , BäcklundLM , ChanR , JonesDT , et al. IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas. Neuro-oncology2009;11:341-7.">Ichimura 2009</a>; <a href="./references#CD007104-bbs2-0013" title="KloosterhofNK , BraltenLB , DubbinkHJ , FrenchPJ , vanden BentMJ . Isocitrate dehydrogenase-1 mutations: a fundamentally new understanding of diffuse glioma?The lancet oncology2011;12:83-91.">Kloosterhof 2011</a>; <a href="./references#CD007104-bbs2-0021" title="ParsonsDW , JonesS , ZhangX , LinJC , LearyRJ , AngenendtP , et al. An integrated genomic analysis of human glioblastoma multiforme. Science2008;321:1807-12.">Parsons 2008</a>; <a href="./references#CD007104-bbs2-0023" title="SonodaY , KumabeT , NakamuraT , KanamoriM , YamashitaY , SuzukiH , et al. Analysis of IDH1 and IDH2 mutations in Japanese glioma patients. Cancer Science2009;100:1996-8.">Sonoda 2009</a>; <a href="./references#CD007104-bbs2-0026" title="WatanabeT , NobusawaS , KleihuesP , OhgakiH . IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. American Journal of Pathology2009;174:1149-53.">Watanabe 2009</a>; <a href="./references#CD007104-bbs2-0027" title="YanH , ParsonsDW , JinG , McLendonR , RasheedBA , YuanW , et al. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine2009;360:765-73.">Yan 2009</a>). The status of the IDH‐1 gene can be determined by immunohistochemistry with an antibody specific to the common mutant form of IDH‐1 (<a href="./references#CD007104-bbs2-0008" title="Camelo-PiraguaS , JansenM , GangulyA , KimJC , LouisDN , NuttCL . Mutant IDH1-specific immunohistochemistry distinguishes diffuse astrocytoma from astrocytosis. Acta Neuropathologica2010;119:509-11.">Camelo‐Piragua 2010</a>). </p> <p>The O<sup>6</sup>‐methylguanine DNA‐methyltransferase (MGMT) gene encodes for a protein responsible for deoxyribonucleic acid (DNA) repair by removing alkyl groups from guanine, and MGMT promoter methylation was shown to be prognostic in GBM (<a href="./references#CD007104-bbs2-0024" title="StuppR , MasonWP , vanden BentMJ , WellerM , FisherB , TaphoornMJ , et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine2005;352:987-96.">Stupp 2005</a>). Its link to the development of gliomas has been assessed, without a clear causal effect demonstrated (<a href="./references#CD007104-bbs2-0005" title="Boots-SprengerSH , SijbenA , RijntjesJ , TopsBB , IdemaAJ , RiveraAL , et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. Modern Pathology2013;26(7):922-9.">Boots‐Sprenger 2013</a>; <a href="./references#CD007104-bbs2-0015" title="LaffaireJ , EverhardS , IdbaihA , CrinièreE , MarieY , deReynièsA , et al. Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-oncology2011;13:84-98.">Laffaire 2011</a>). Its role as a biomarker for AO and AOA is not yet well defined. </p> </section> <section id="CD007104-sec-0011"> <h3 class="title" id="CD007104-sec-0011">Why it is important to do this review</h3> <p>In this systematic review, we sought to identify the role of sequential RT and chemotherapy compared with RT alone in adults with newly diagnosed AO or AOA; and to evaluate the predictive and prognostic impact of the following biomarkers: codeletion of chromosomes 1p and 19q, MGMT promotor methylation, and IDH‐1and ‐2 mutations. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007104-sec-0012" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007104-sec-0012"></div> <p>To compare postoperative sequential RT and chemotherapy to RT alone in adults with newly diagnosed AO or mixed AOA. To evaluate the predictive and prognostic impact of the following markers: codeletion of chromosomes 1p and 19q, MGMT promoter methylation, and IDH‐1and ‐2 mutations. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007104-sec-0013" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007104-sec-0013"></div> <section id="CD007104-sec-0014"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007104-sec-0015"> <h4 class="title">Types of studies</h4> <p>All randomized controlled trials (RCTs) that limited enrolment to participants with AO, AOA or AA. </p> </section> <section id="CD007104-sec-0016"> <h4 class="title">Types of participants</h4> <p>Adults over 18 years of age with a diagnosis of AO, AOA or AA.</p> </section> <section id="CD007104-sec-0017"> <h4 class="title">Types of interventions</h4> <p>After surgery, participants were randomized to receive RT alone, chemotherapy alone or RT plus chemotherapy. No chemotherapy regimens were excluded. </p> </section> <section id="CD007104-sec-0018"> <h4 class="title">Types of outcome measures</h4> <section id="CD007104-sec-0019"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007104-list-0001"> <li> <p>OS: as defined from date of randomization to death from of any cause.</p> </li> </ul> </p> </section> <section id="CD007104-sec-0020"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007104-list-0002"> <li> <p>PFS: as defined from date of randomization to disease progression based on clinical or radiographic evidence. </p> </li> <li> <p>Treatment toxicity of grade 3 or greater.</p> </li> </ul> </p> </section> </section> </section> <section id="CD007104-sec-0021"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007104-sec-0022"> <h4 class="title">Electronic searches</h4> <p>The search was run for the original review in August 2006, and subsequently updated in Mar 2014. </p> <p>We searched the following databases:</p> <p> <ul id="CD007104-list-0003"> <li> <p>Cochrane Central Register for Controlled Trials (CENTRAL) (Issue 1, 2014).(<a href="./appendices#CD007104-sec-0064">Appendix 1</a>); </p> </li> <li> <p>MEDLINE (up to March week 2 2014) (<a href="./appendices#CD007104-sec-0065">Appendix 2</a>); </p> </li> <li> <p>EMBASE (up to 2014 week 11) (<a href="./appendices#CD007104-sec-0066">Appendix 3</a>). </p> </li> </ul> </p> <p>We examined the reference lists from relevant articles and review articles to search for any additional articles. </p> </section> <section id="CD007104-sec-0023"> <h4 class="title">Searching other resources</h4> <p>We searched no other resource, as we included only RCTs in this review.</p> </section> </section> <section id="CD007104-sec-0024"> <h3 class="title" id="CD007104-sec-0024">Data collection and analysis</h3> <section id="CD007104-sec-0025"> <h4 class="title">Selection of studies</h4> <p>We applied the search criteria and reviewed all titles and abstracts identified. Studies in which the relevance was unclear were further examined by retrieving the full article. All authors agreed on the study selection. We used the bibliographic software Endnote. </p> </section> <section id="CD007104-sec-0026"> <h4 class="title">Data extraction and management</h4> <p>For included studies, we have extracted the following data:</p> <p> <ul id="CD007104-list-0004"> <li> <p>author, year of publication and journal citation (including language);</p> </li> <li> <p>country;</p> </li> <li> <p>setting;</p> </li> <li> <p>inclusion and exclusion criteria;</p> </li> <li> <p>study design, methodology;</p> </li> <li> <p>study population</p> <ul id="CD007104-list-0005"> <li> <p>total number enrolled,</p> </li> <li> <p>participant characteristics,</p> </li> <li> <p>age,</p> </li> <li> <p>histological diagnosis,</p> </li> <li> <p>number of anaplastic characteristic,</p> </li> <li> <p>biomarkers status (codeletion of chromosomes 1p and 19q, IDH‐1 and ‐2 mutations, MGMT methylation); </p> </li> </ul> </li> <li> <p>intervention details</p> <ul id="CD007104-list-0006"> <li> <p>RT dose and fractionation,</p> </li> <li> <p>chemotherapy agents, dose and number of cycles,</p> </li> <li> <p>timing of intervention following surgery,</p> </li> <li> <p>toxicity of intervention;</p> </li> </ul> </li> <li> <p>comparison</p> <ul id="CD007104-list-0007"> <li> <p>timing of assessment of biomarkers (at time of accrual versus after accrual),</p> </li> <li> <p>definition of progression,</p> </li> <li> <p>treatment at progression;</p> </li> </ul> </li> <li> <p>risk of bias in study (see <a href="#CD007104-sec-0040">Risk of bias in included studies</a>); </p> </li> <li> <p>duration of follow‐up;</p> </li> <li> <p>outcomes: for each outcome, we extracted the outcome definition and unit of measurement (when relevant). For adjusted estimates, we recorded variables adjusted for in analyses; </p> </li> <li> <p>results: we extracted the number of participants allocated to each intervention group, the total number analyzed for each outcome, and the missing participants. </p> </li> </ul> </p> <p>In a future update, if a meta‐analysis can be performed, the following methodology would be considered, with results extracted as follows: </p> <p> <ul id="CD007104-list-0008"> <li> <p>For time to event data (survival and disease progression), we would extract the log of the hazard ratio (log(HR)) and its standard error from trial reports. If these are not reported, we would attempt to estimate the log(HR) and its standard error using the methods of Parmar (<a href="./references#CD007104-bbs2-0020" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815-34.">Parmar 1998</a>). </p> </li> <li> <p>For dichotomous outcomes (e.g. adverse events or deaths, if it is not possible to use a HR), we will extract the number of participants in each treatment arm who experienced the outcome of interest and the number of participants assessed at endpoint, in order to estimate a risk ratio. </p> </li> <li> <p>For continuous outcomes (e.g. quality of life (QoL) measures), we will extract the final value and standard deviation of the outcome of interest and the number of participants assessed at endpoint in each treatment arm at the end of follow‐up, in order to estimate the mean difference between treatment arms and its standard error. </p> </li> </ul> </p> </section> <section id="CD007104-sec-0027"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We assessed the risk of bias in included studies using The Cochrane Collaboration's tool (<a href="./references#CD007104-bbs2-0011" title="HigginsJP , AltmanDG , GøtzschePC , JüniP , MoherD , OxmanAD , et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ2011;343:d5928.">Higgins 2011</a>). This included an assessment of: </p> <p> <ol id="CD007104-list-0009"> <li> <p>selection bias: random sequence generation and allocation concealment;</p> </li> <li> <p>performance bias: blinding of participants and personnel (participants and treatment providers); </p> </li> <li> <p>detection bias: blinding of outcome assessment;</p> </li> <li> <p>attrition bias: incomplete outcome data;</p> </li> <li> <p>reporting bias: selective reporting of outcomes.</p> </li> </ol> </p> <p>We classified the risk of these biases as 'low', 'high' or 'unclear' for each included study (<a href="./references#CD007104-sec-0075" title="">Characteristics of included studies</a>). </p> </section> <section id="CD007104-sec-0028"> <h4 class="title">Measures of treatment effect</h4> <p>If the trials had had homogeneous patients' characteristics and interventions, we would have evaluated measures of treatment effect. </p> <p> <ul id="CD007104-list-0010"> <li> <p>For OS and PFS, we would have extracted the log(HR) and its standard error from trial reports. </p> </li> <li> <p>For toxicity, we would have extracted the number of participants in each treatment arm who experienced toxicity of grade 3 or greater and the number of participants assessed at endpoint, in order to estimate a risk ratio. </p> </li> </ul> </p> </section> <section id="CD007104-sec-0029"> <h4 class="title">Dealing with missing data</h4> <p>We contacted the authors from the three trials to request further details. The principle investigator of the Radiation Therapy Oncology Group (RTOG) trial, Gregory Cairncross, informed us that an update on the trial, including information on IDH‐1 and ‐2 mutations status, was to be published. This update was included in our review. No information beyond what is currently published was available for the two other trials. </p> </section> <section id="CD007104-sec-0030"> <h4 class="title">Assessment of heterogeneity</h4> <p>The included studies present significant differences.</p> <p> <ul id="CD007104-list-0011"> <li> <p>Clinical diversity: the histological diagnosis of participants in the three studies differ, with different criteria for anaplasia in all studies and inclusion of AA in the NOA‐04 study; the interventions are different in the three studies, with varying dosing and schedules of chemotherapy, with different sequences of treatment and with different chemotherapy agents being used. </p> </li> <li> <p>Methodological diversity: the European Organisation for Research and Treatment of Cancer (EORTC) trial analyzed their results on an intention‐to‐treat (ITT) basis, whereas the RTOG and NOA‐04 trials performed their statistical analyses on a participant eligible basis and modified ITT, respectively. </p> </li> </ul> </p> </section> <section id="CD007104-sec-0031"> <h4 class="title">Assessment of reporting biases</h4> <p>We intended to construct a funnel plot of treatment effect versus precision in order to investigate the likelihood of publication bias if we had identified 10 or more studies. If these plots had suggested that treatment effects may not be sampled from a symmetric distribution, as assumed by the random‐effects model, we had planned to perform further meta‐analyses using the fixed‐effect model. </p> </section> <section id="CD007104-sec-0032"> <h4 class="title">Data synthesis</h4> <p>The results of the three selected studies were not amenable to a meta‐analysis because of participant selection with respect to the pathological diagnosis (inclusion of AA in the NOA‐04 study, and different criteria to define anaplasia), and also because of sequence of treatment (RT and chemotherapy). Therefore, we have described the results separately for each RCT. </p> </section> <section id="CD007104-sec-0033"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>If the trials had had homogeneous participants' characteristics and interventions, we would have performed subgroup analysis with regards to biomarker status. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007104-sec-0034" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007104-sec-0034"></div> <section id="CD007104-sec-0035"> <h3 class="title">Description of studies</h3> <section id="CD007104-sec-0036"> <h4 class="title">Results of the search</h4> <p>For the updated review, the search found 70 publications on CENTRAL, 278 on MEDLINE and 193 on EMBASE. </p> </section> <section id="CD007104-sec-0037"> <h4 class="title">Included studies</h4> <p>Three RCTs met the inclusion criteria. Two were included in the first Cochrane review in 2008 (<a href="./references#CD007104-bbs2-0028" title="QuonH , AbdulkarimB . Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD007104]">Quon 2008</a>). Several updates with analysis of biomarkers were published for both studies. The third study was published after the first review was developed. </p> <p>The RTOG trial 9402 was a multicentre RCT (1994 to 2002) that included 289 participants older than 18 years of age with AO or AOA (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>). Since the first publication in 2006, three published updates have addressed the outcomes that we are evaluating, and the median follow‐up is now 11.3 years. Anaplasia was identified based on five features (tumour cellularity, nuclear pleomorphism, mitotic activity, endothelial proliferation and necrosis). Anaplastic tumours had to contain two of five features, one of which was high mitotic activity or endothelial proliferation. An oligoastrocytoma had to have at least 25% oligodendroglioma component. Participants had a Karnofsky Performance Scale (KPS) score of at least 60 and were randomized within eight weeks of surgery and received up to four cycles of PCV followed by RT (147 participants) versus RT alone (142 participants). RT was identical in both treatment arms and was given to a total dose of 59.4 Gy in 33 fractions. Unplanned analysis of codeletion of chromosomes 1p and 19q by fluorescence in situ hybridization (FISH) analysis, and of IDH‐1 and ‐2 mutations by immunohistochemistry and sequencing, started after the initiation of the trial as the importance of these markers was not known until after participant accrual had begun. The codeletion of chromosomes 1p and 19q status was obtained for 91% of the participants in the update of the study, as compared with only 70% in the original. The IDH‐1 and ‐2 status was obtained in 72% of the participants. The primary endpoint was OS and secondary endpoints included PFS, frequency of severe (grade 3 or greater) treatment toxicities, cognition and QoL. </p> <p>The EORTC trial 26951 was a multicentre RCT (1996 to 2002) that included 368 participants aged 16 to 70 years with newly diagnosed AO or AOA (<a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). Since the first publication in 2006, eight published updates have addressed the outcomes that we are evaluating, and the median follow‐up is now 11.7 years. In contrast to RTOG 9402, anaplastic tumours were defined as having at least three of five anaplastic features (high cellularity, mitosis, nuclear abnormalities, endothelial proliferation and necrosis). An oligoastrocytoma had to have at least 25% oligodendroglioma component. Participants with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 were eligible and randomized after surgery to either RT (59.4 Gy in 33 fractions) followed by up to 6 cycles of PCV (185 participants) versus RT alone (183 participants). As with the RTOG trial, assessment of codeletion of chromosomes 1p and 19q by FISH analysis was not started until the trial had begun and was available for 85.9% of participants. The assessment of MGMT methylation by semi‐quantitative methylation‐specific multiplex ligation‐dependent probe amplification and of IDH‐1 and ‐2 mutations by bidirectional cycle sequencing of polymerase chain reaction (PCR)‐amplified fragments was done after the conclusion of enrolment for the study. Information on the MGMT methylation and on IDH‐1 and ‐2 was found for 49.7% and 48.6% of participants, respectively. Primary endpoints were OS and PFS, and secondary endpoints included QoL and toxicity. </p> <p>The Neuro‐Oncology Working Group (NOA) of the German Cancer Society 04 was a multicentre RCT (1999 to 2005) that included 274 participants aged 18 years and over with newly diagnosed AO, AOA or AA who were followed for a maximum of 4.5 years (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>). Similarly to the EORTC study, at least three criteria of anaplastic features were required for the tumours to be defined anaplastic. Participants had a KPS score of 70 or greater, and were randomized in a 2:1:1 fashion to 60 Gy in 30 to 33 fractions of RT (139 participants) versus 4 cycles of 8 weeks of PCV (68 participants) versus 8 cycles of 4 weeks of temozolomide (67 participants). In contrast to the RTOG and EORTC studies, molecular analyses was assessed at randomization. Assessment of codeletion of chromosomes 1p and 19q was carried out by a multiplex ligation‐dependent probe assay and was available for 56.9% of participants. MGMT methylation status was determined in 63.5% of participants by methylation‐specific PCR. IDH‐1 and ‐2 mutations were evaluated by gene amplification, and results were available for 61.3% of participants. The primary endpoint was time from operation to treatment failure. Secondary endpoints included response rate, PFS, OS, time to treatment failure stratified for histology, codeletion of chromosomes 1p and 19q, MGMT promoter methylation status, IDH‐1 mutation and toxicity. </p> <p>These studies are summarized in <a href="#CD007104-tbl-0001">Table 1</a>. </p> <div class="table" id="CD007104-tbl-0001"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of the studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RTOG 9402</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EORTC 26951</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOA‐04</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Histology</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AO and AOA with at least 25% oligodendroglial elements</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AO and AOA with at least 25% oligodendroglial elements</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AO, AOA and AA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pathological characteristics</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 of 5: high cellularity, nuclear polymorphism, mitotic activity, endothelial proliferation and necrosis </p> <p>At least 1 needs to be mitosis or endothelial proliferation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 of 5: high cellularity, mitosis, nuclear abnormalities, endothelial proliferation and necrosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 of 4: high cellularity, mitotic activity, nuclear polymorphism and vascular proliferation</p> <p>No necrosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate of codeletion of chromosomes 1p and 19q</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.9%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants randomly assigned</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>274</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomization arms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ RT + PCV intensive regimen 4 cycles prior to RT (n = 147)</p> <p>‐ RT alone (n = 142)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ RT + PCV 6 cycles after RT (n = 185)</p> <p>‐ RT alone (n = 183)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ RT first, chemotherapy at recurrence (n = 139)</p> <p>‐ chemotherapy first, RT at recurrence (n = 135)</p> <p>PCV 4 cycles (n = 68)</p> <p>Temozolomide 8 cycles (n = 67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate of chemotherapy a time of recurrence in RT arms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median survival</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 4.6 years for RT plus PCV</p> <p>‐ 4.7 years for RT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 3.5 years for RT plus PCV</p> <p>‐ 2.6 years for RT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 6.0 years for RT first</p> <p>‐ 6.9 years for chemotherapy first</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Loss of heterozygosity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic and predictive for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic for PFS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MGMT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not prognostic for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic for PFS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IDH‐1 or ‐2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic and predictive for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic for PFS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author's clinical conclusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For the subset of participants with 1p/19q codeleted or IDH‐1 or ‐2 mutated AO/AOA, PCV plus RT may be an especially effective treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCV plus RT increases both OS and PFS in AO/AOA. Codeleted tumours derive more benefit from adjuvant PCV compared with non‐codeleted tumours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Initial RT or chemotherapy achieved comparable results in participants with anaplastic gliomas </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>AA: anaplastic astrocytoma; AO: anaplastic oligodendroglioma; AOA: anaplastic oligoastrocytoma; IDH: isocitrate dehydrogenase; MGMT: O<sup>6</sup>‐methylguanine‐DNA methyltransferase; NA: not applicable; OS: overall survival; PCV: procarbazine, lomustine and vincristine; PFS: progression‐free survival; RT: radiotherapy. </p> </div> </div> <section id="CD007104-sec-0038"> <h5 class="title">Limitations of studies</h5> <p>These three studies have significant differences worth mentioning.</p> <p>First, there are noteworthy pathological characteristic distinctions in each study. The RTOG and EORTC studies included AOA and AO only. However, the number of anaplastic characteristics a tumour required to be defined anaplastic differed in each study. Two criteria were required in the RTOG study, as long as high mitotic activity or endothelial proliferation was present. The EORTC study based the diagnosis of anaplastic tumours on the WHO 1993 grading, requiring three criteria, including tumours with necrosis. The NOA‐04 study included not only AO and AOA, but also AA. In this study, grading of tumours was based on the WHO 2000 grading, requiring three criteria of anaplasia excluding necrosis. </p> <p>Second, assessment of chromosome 1p and 19q deletions and IDH‐1 and ‐2 mutations were started after participant accrual had begun in the RTOG and EORTC studies. As a result, these studies assessed chromosome deletions and mutations in different proportions of their participant populations. As for MGMT methylation, it was not assessed in the RTOG study, and the EORTC group only began the analysis after the start of participant accrual. In contrast, all molecular analyses in the NOA‐04 study were intended in the initial protocol. </p> <p>Third, the treatments given were different. The RTOG and EORTC studies, although both comparing RT alone versus RT plus chemotherapy, had different sequences of treatment and doses of PCV in the experimental arms, with the RTOG 9402 study treating with up to four cycles of standard PCV prior to RT, and the EORTC 26951 trial delivering up to six cycles of standard PCV after RT. The chemotherapy arms of the NOA‐04 included four cycles of higher dose PCV as well as eight cycles of temozolomide. The NOA‐04 also standardized the treatments to be received at time of failure, with chemotherapy given to participants randomized to RT and vice‐versa. </p> </section> </section> <section id="CD007104-sec-0039"> <h4 class="title">Excluded studies</h4> <p>We screened 467 records and excluded 453 records (<a href="#CD007104-fig-0001">Figure 1</a>): </p> <div class="figure" id="CD007104-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007104-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007104.pub2/media/CDSR/CD007104/image_n/nCD007104-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> <p> <ul id="CD007104-list-0012"> <li> <p>401 were not RCTs;</p> </li> <li> <p>41 were not restricted to grade III gliomas</p> </li> <li> <p>four did not randomize participants to receive RT alone, chemotherapy alone or RT plus chemotherapy; </p> </li> <li> <p>four included a paediatric population;</p> </li> <li> <p>two did not address the outcomes of OS, PFS or toxicity of grade 3 or greater;</p> </li> <li> <p>one was only in abstract form.</p> </li> </ul> </p> </section> </section> <section id="CD007104-sec-0040"> <h3 class="title">Risk of bias in included studies</h3> <p>The three trials randomized participants at a central data centre and used either a randomized permuted block within each stratification cell or a minimization technique to balance the treatment groups with respects to stratification factors. </p> <p>Central pathology review was carried out in each study. However, the EORTC study included participants in which there was discrepancy between local and central pathology diagnosis, whereas the RTOG and NOA‐04 trials had central pathology review prior to study entry. </p> <p>The EORTC trial analyzed their results on an ITT basis, whereas the RTOG and NOA‐04 trials performed their statistical analysis on a participant eligible basis and modified ITT, respectively. </p> <p>In the three studies, the participants in each treatment arms were balanced with respect to known prognostic factors. </p> <section id="CD007104-sec-0041"> <h4 class="title">Allocation</h4> <p>In the RTOG and EORTC trials, there was low risk of allocation bias as stratification factors were taken into account at randomization. In the NOA‐04 study, there was unclear risk of allocation bias as there was no clear indication of stratification. </p> </section> <section id="CD007104-sec-0042"> <h4 class="title">Blinding</h4> <p>There was high risk of performance and detection bias in the three studies, as none was blinded. However, blinding would have been practically impossible given the nature and side effects of the treatments. </p> </section> <section id="CD007104-sec-0043"> <h4 class="title">Incomplete outcome data</h4> <p>There was an unknown risk of attrition bias in the three studies, as none reported loss to follow‐up. </p> </section> <section id="CD007104-sec-0044"> <h4 class="title">Selective reporting</h4> <p>There was low risk of reporting bias in the three studies, as outcomes were reported adequately. </p> </section> <section id="CD007104-sec-0045"> <h4 class="title">Other potential sources of bias</h4> <p>No other source of bias was found in the studies.</p> </section> </section> <section id="CD007104-sec-0046"> <h3 class="title" id="CD007104-sec-0046">Effects of interventions</h3> <section id="CD007104-sec-0047"> <h4 class="title">Overall survival</h4> <p>Only one study was able to demonstrate a statistically significant OS benefit for one of the treatment arms. In the EORTC trial, median OS in the RT plus PCV arm was 3.5 years compared with 2.6 years in the RT alone arm (HR 0.75; 95% confidence interval (CI) 0.60 to 0.95; P value = 0.018). This result was reported 10 years after the conclusion of the enrolment, and was not apparent in the first analysis. In the RTOG trial, median OS in the PVC plus RT arm was 4.6 years and in the RT alone group was 4.7 years (HR 0.79; 95% CI 0.60 to 1.04; P value = 0.1). In the NOA‐04 study, median OS was 6.0 years in the RT arm compared with 6.9 years in the chemotherapy first arm. The OS advantage found in the EORTC trial might in part be explained by the inclusion of tumours with necrosis, which is more consistent with a diagnosis of GBM (<a href="./references#CD007104-bbs2-0014" title="KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46.">Kouwenhoven 2009</a>), for which the Stupp trial showed an OS advantage with combined chemo‐radiotherapy (<a href="./references#CD007104-bbs2-0024" title="StuppR , MasonWP , vanden BentMJ , WellerM , FisherB , TaphoornMJ , et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. New England Journal of Medicine2005;352:987-96.">Stupp 2005</a>). </p> </section> <section id="CD007104-sec-0048"> <h4 class="title">Progression‐free survival</h4> <p>In the review of 2008 (<a href="./references#CD007104-bbs2-0028" title="QuonH , AbdulkarimB . Adjuvant treatment of anaplastic oligodendrogliomas and oligoastrocytomas. Cochrane Database of Systematic Reviews2008, Issue 2. [DOI: 10.1002/14651858.CD007104]">Quon 2008</a>), it was already clear that sequential RT with PCV improved the PFS in a statistically significant way. Whereas the RTOG group did not update their result on this outcome, the update of the EORTC group reported PFS of 2.0 years after RT plus PCV compared with 1.1 years after RT alone (HR 0.66; 95% CI 0.52 to 0.83; P value = 0.0003). The NOA‐04 trial found a PFS of 2.6 years in the RT arm compared with 2.7 years in the CT arm (HR 1.0; P value = 0.87), supporting the idea that the efficacy of sequential treatment is not influenced by the order of treatment. </p> </section> <section id="CD007104-sec-0049"> <h4 class="title">Biomarkers</h4> <section id="CD007104-sec-0050"> <h5 class="title">Codeletion of chromosomes 1p and 19q</h5> <p>The analysis of codeletion of chromosomes 1p and 19q was unplanned in the RTOG and EORTC trials. In the RTOG study, of the participants who were assessed for codeletion of chromosomes 1p and 19q, loss of 1p was detected in 54.2% and loss of 19q in 63.3%. Combined 1p and 19q deletions were present in 47.9%. Combined loss was associated with prolonged survival in both treatment arms, and improved survival with combination treatment in participants with codeleted tumours. The median OS for participants with codeletion of chromosomes 1p and 19q was 14.7 years in the chemotherapy plus RT arm versus 7.3 years in the RT alone arm (HR 0.59; 95% CI 0.37 to 0.95; P value = 0.03). Participants without codeletion of chromosomes 1p and 19q did not have significant differences in OS according to the treatment arm, with median survival of 2.6 years after chemotherapy plus RT versus 2.7 years after RT alone (HR 0.85; 95% CI 0.56 to 1.16; P value = 0.24), supporting codeletion as a predictive factor for OS. Codeletion of chromosomes 1p and 19q was also associated with prolonged PFS, with median PFS 8.4 years for participants treated with chemotherapy plus RT versus 2.9 years for participants treated with and RT alone(HR 0.47; 95% CI 0.3 to 0.72; P value &lt; 0.001). No statistically significant difference in PFS was seen in participants without codeletion, with PFS of 1.2 years after chemotherapy and RT compared with 1.0 years after RT alone (HR 0.81; 95% CI 0.56 to 1.16; P value = 0.24) (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>). </p> <p>In the EORTC trial, codeletion of chromosomes 1p and 19q was detected in 25.3% of participants for whom tissue was available for assessment. The median OS for participants with 1p and 19q codeletion was not reached in the RT plus chemotherapy arm versus 9.3 years in the RT alone arm (HR 0.56; 95% CI 0.31 to 1.03; P value = 0.059). The survival of participants without codeletion did not have significant differences according to the treatment arm, with median survival of 2.1 years after RT plus chemotherapy versus 1.8 years after RT alone (HR 0.83; 95% CI 0.62 to 1.1; P value = 0.185). Although there was a trend for codeletion to be a predictive factor for OS, it did not reach statistical significance. The PFS of participants with codeletion of chromosomes 1p and 19q who received PCV plus RT compared with RT alone was higher with PFS of 13.1 years with PCV plus RT versus 4.2 years with RT alone (HR 0.42; 95% CI 0.24 to 0.74; P value = 0.002). A smaller improvement in PFS was also observed in the non‐codeleted group, with combined treatment resulting in 1.3 years of PFS compared with 0.8 years in participants treated with RT alone (HR 0.73; 95% CI 0.56 to 0.97; P value = 0.026) (<a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). </p> <p>In the NOA‐04 study, the analysis of codeletion of chromosomes 1p and 19q was planned. Of the participants who were assessed for this biomarker, loss of 1p alone was detected in 26.5% of participants and loss of 19q alone in 20.4% of participants. Codeletion of chromosomes 1p and 19q was present in 40.9% of participants. No information on the effect of codeletion and treatment arm on OS or PFS was provided by the authors. On univariate analysis, participants with no codeletion had lower PFS in comparison with participants with codeletion (HR 3.2; 95% CI 2.0 to 5.0; P value &lt; 0.001). On multivariate analysis, codeletion status remained a significant prognostic factor for PFS (HR 2.1; 95% CI 1.2 to 3.7; P value &lt; 0.0092) (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>). </p> </section> <section id="CD007104-sec-0051"> <h5 class="title">Isocitrate dehydrogenase‐1 or isocitrate dehydrogenase‐2 mutations</h5> <p>The analysis of IDH‐1 mutation was unplanned in the RTOG and EORTC trials.</p> <p>The RTOG group found IDH‐1 or ‐2 to be mutated in 74% of evaluated participants. The survival for participants with IDH‐1 or ‐2 mutations was 9.4 years in the chemotherapy plus RT arm versus 5.7 years in the RT alone arm (HR 0.59; 95% CI 0.40 to 0.86). In the latest analysis of the RTOG study, some participants without codeletion of chromosomes 1p and 19q still had benefit from combined PCV and RT. Participants without codeletion of chromosomes 1p and 19q but with IDH‐1 or ‐2 mutations were found to have longer survival after chemotherapy plus RT compared with RT alone (5.5 years with chemotherapy plus RT versus 3.3 years with RT alone; HR 0.56; 95% CI 0.32 to 0.99). The survival of participants without IDH‐1 or ‐2 mutations did not show significant differences with survival of 1.3 years after chemotherapy plus RT versus 1.8 years after RT alone (HR 1.14; 95% CI 0.63 to 2.04). Therefore, IDH‐1 or ‐2 mutations were predictive for OS (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>). </p> <p>The EORTC group found IDH‐1 to be mutated in 44.9% of evaluated participants. The median OS for participants with IDH‐1 mutation was not reached in the RT plus chemotherapy arm versus 5.4 years in the RT alone arm (HR 0.53; 95% CI 0.30 to 0.95). The OS of participants without IDH‐1 mutation showed no significant differences according to the treatment arm, with median survival of 1.6 years after RT plus chemotherapy versus 1.2 years after RT alone (HR 0.78; 95% CI 0.52 to 1.8). Although OS did not reach statistical significance, there was a trend for IDH mutation to be predictive of OS. In multivariate analysis, IDH‐1 mutation and codeletion of chromosomes 1p and 19q were found to be independent prognostic factors for OS. The PFS of participants with IDH‐1 mutation who received PCV plus RT compared with RT alone was higher with PFS of 5.9 years with chemotherapy plus RT versus 3.0 years with RT alone (HR 0.49; 95% CI 0.29 to 0.84). A smaller improvement in PFS was also observed in the non‐mutated group, with combined treatment resulting in 0.8 years of PFS compared with 0.6 years in participants treated with RT alone (HR 0.56; 95% CI 0.37 to 0.86) (<a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). </p> <p>In the NOA‐04 trial, the analysis of IDH‐1 mutation was planned. A large proportion (65.6%) of evaluated participants were found to have mutation in IDH‐1. No information on the effect of IDH‐1 mutation and treatment arm on OS or PFS were provided by the authors. On univariate analysis, participants with no mutation had lower PFS in comparison to participants with mutation (HR 2.4; 95% CI 1.7 to 3.5; P value &lt; 0.001). In the multivariate model, absence of IDH‐1 mutation was still associated with a lower PFS (HR 2.1; 95% CI 1.3 to 3.3; P value = 0.0021) (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>). </p> </section> <section id="CD007104-sec-0052"> <h5 class="title">O<sup>6</sup>‐Methylguanine‐DNA methyltransferase methylation </h5> <p>The analysis of MGMT methylation was not done in the RTOG trial, and was unplanned in the EORTC trial. </p> <p>In the EORTC trial, the MGMT promoter was methylated in 43.7% of evaluated participants. The median OS for participants with MGMT methylation was 5.9 years in the RT plus chemotherapy arm versus 3.6 years in the RT alone arm (HR 0.65; 95% CI 0.43 to 0.98). The survival of participants without MGMT methylation did showed no significant differences according to the treatment arm, with median survival of 1.4 years after RT plus chemotherapy versus 1.3 years after RT alone (HR 0.81; 95% CI 0.44 to 1.49). The PFS of participants with MGMT methylation who received PCV plus RT compared with RT alone was higher with PFS of 4.6 years with PCV plus RT versus 1.3 years with RT alone (HR 0.52; 95% CI 0.35 to 0.76). No statistically significant improvement in PFS was observed in the non‐methylated group, with combined treatment resulting in 0.8 years of PFS compared with 0.6 years in participants treated with RT alone (HR 0.63; 95% CI 0.34 to 1.16). In multivariate analysis, MGMT methylation did not affect OS (<a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). </p> <p>In the NOA‐04 trial, the analysis of MGMT methylation was planned. Of the evaluated participants, 60.9% were found to have a methylated MGMT promoter. On univariate analysis, participants with the MGMT promoter gene unmethylated had lower PFS in comparison to participants with methylation (HR 2.0; 95% CI 1.4 to 2.9; P value &lt; 0.001). In the multivariate analysis, unmethylated MGMT was associated with shorter PFS (HR 1.7; 95% CI 1.1 to 2.7; P value = 0.0216). Moreover, MGMT methylation was associated with a better PFS not only in the chemotherapy arms with an HR of 2.7 (95% CI 1.4 to 5.1; P value = 0.003), but also in the RT arm with an HR of 2.0 (95% CI 1.1 to 3.6; P value = 0.03) (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>). </p> </section> </section> <section id="CD007104-sec-0053"> <h4 class="title">Treatment toxicity</h4> <p>In the review of 2008, it was found that participants treated with combined modality experienced significant toxicity in both the RTOG and EORTC trials. </p> <p>The RTOG group reported that 54% of the participants randomized to upfront chemotherapy plus RT received the four cycles of PCV as planned. They updated their results and there are now two early deaths attributable to PCV‐induced neutropenia reported, as compared with only one in 2006. Severe late effects remained uncommon. In addition, both groups had similar Mini Mental Status Examination and QoL scores until the last years of life, when scores declined rapidly (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>). </p> <p>The EORTC group did not update toxicity results, and 30% of the participants randomized to the upfront chemotherapy plus RT arm received the six cycles as intended (<a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). </p> <p>In the NOA‐04 trial, 3% of participants undergoing RT experienced treatment interruption, as compared with 18% of participants undergoing PCV and 6% of participants undergoing temozolomide. Interruptions in the chemotherapy arms were related to haematological toxicity. All participants in the RT arm completed treatment. In the PCV arm, 9% of participants discontinued treatment, and dose reduction was required in 16% of participants. In the temozolomide arm, no discontinuation was required; however, dose reduction was required in 6% of participants (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>). </p> </section> <section id="CD007104-sec-0054"> <h4 class="title">Treatment at progression</h4> <p>Many participants in the three trials who were randomized to RT alone received chemotherapy at progression. Seventy‐nine per cent of participants in the RT group in the RTOG study (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>), 74.5% in the EORTC trial (<a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>), and 48% in the NOA‐04 trial (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>) received chemotherapy at progression. Surgery at progression was less frequent. In the RTOG trial, 43% of the chemotherapy plus RT arm and 56% of the RT arm were operated at the time of progression (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>). In the EORTC trial, surgery at progression was given in 22.6% of participants in the chemotherapy plus RT arm and 18.6% of participants in the RT arm (<a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). No information on surgery rates at time of progression was reported in the NOA‐04 trial (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>). </p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007104-sec-0055" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007104-sec-0055"></div> <section id="CD007104-sec-0056"> <h3 class="title" id="CD007104-sec-0056">Summary of main results</h3> <p>Although there is no consensus established yet for the treatment of anaplastic gliomas, results from three large RCTs are now leading to treatment decision based on codeletion of chromosomes 1p and 19q and IDH status. </p> <p>Both the RTOG and the EORTC studies suggest that upfront treatment with both PCV and RT improves OS in participants with codeleted or IDH‐1 or ‐2 (or both) mutated tumours (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>; <a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). Furthermore, in the most recent RTOG analysis, upfront combined treatment improved OS of participants without 1p and 19q codeletion but with IDH‐1 or ‐2 mutation. Participants without either codeletions or IDH mutations did not seem to benefit from the addition of PCV (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>). In the EORTC trial, no conclusions were reached in this subgroup of participants. Nonetheless, there was a trend for codeletion and IDH‐1 mutation to predict OS according to treatment arm (<a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). The NOA‐04 study does not, for the moment, have enough follow‐up to determine if participants with codeleted or IDH (or both) mutated tumours have a better survival depending on treatment arm (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>). </p> <p>A striking difference between these studies was the difference in OS. The longest OS was reported by the NOA‐04 study, with 6.0 years for the treatment arm of RT followed by chemotherapy and 6.9 years for chemotherapy arm followed by RT at the time of progression (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>). In the RTOG trial, the median OS for the combined treatment arm was 4.6 years as compared with 4.7 years for the sequential treatment arm (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>). In the EORTC trial, the median OS was of 3.5 years for the combined treatment arm as compared to 2.6 years for the RT first arm (<a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). Despite the inclusion of AA in the NOA‐04 study, a histology that is generally thought to be associated with poorer prognosis, it still reports the longest OS. The shorter survival in the EORTC trial may be secondary to the lower rate of codeletion and the inclusion of participants with necrosis, which would nowadays be classified as GBM. </p> </section> <section id="CD007104-sec-0057"> <h3 class="title" id="CD007104-sec-0057">Benefit of chemotherapy in anaplastic oligodendrogliomas and anaplastic oligoastrocytomas</h3> <p>Given that these three studies present significant differences in their design and participant population, certain principles still emanate. The RT alone treatment arms from the three studies should be seen as deferral of chemotherapy. In RTOG and EORTC, most participants in the RT alone arm received chemotherapy at the time of progression (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>; <a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). However, the NOA‐04 trial incorporated the idea of sequential treatment as standard treatment in the study design (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>). Therefore, the term RT alone can be seen as a misnomer, and the term sequential treatment should prevail. </p> <p>In spite of the apparent benefit of adding PCV to RT in codeleted and IDH‐1 or ‐2 mutated tumours, many oncologists are concerned about the significant toxicity, haematological and non‐haematological, associated with this regimen. The long survival of participants with AO and AOA reinforces this concern. Commonly, PCV is replaced by temozolomide in this population. Although with limited follow‐up and not powered to compare chemotherapy regimens, the NOA‐04 revealed no difference in OS between PCV and temozolomide. Nevertheless, long‐term data on the efficacy of temozolomide for AO and AOA are lacking. Furthermore, one large retrospective study from Lassman et al. suggested an improved survival in participants treated with PCV alone as compared with temozolomide alone, with a median time to progression of 7.6 years versus 3.3 years, respectively (P value = 0.019) (<a href="./references#CD007104-bbs2-0016" title="LassmanAB , IwamotoFM , CloughesyTF , AldapeKD , RiveraAL , EichlerAF , et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncology2011;13:649-59.">Lassman 2011</a>). </p> </section> <section id="CD007104-sec-0058"> <h3 class="title" id="CD007104-sec-0058">Prognostic and predictive biomarkers</h3> <p>Both the EORTC and the RTOG trials support codeletion of chromosomes 1p and 19q to be an independent prognostic factor for PFS and OS (<a href="./references#CD007104-bbs2-0001" title="CairncrossG , BerkeyB , ShawE , JenkinsR , ScheithauerB , BrachmanD , et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. Journal of Clinical Oncology2006;24(18):2707-14. CairncrossG , WangM , ShawE , JenkinsR , BrachmanD , BucknerJ , et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. Journal of Clinical Oncology2013;31:337-43. CairncrossJG , WangM , JenkinsRB , ShawEG , GianniniC , BrachmanDG , et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH. Journal of Clinical Oncology2014;32(8):783-90. GianniniC , BurgerPC , BerkeyBA , CairncrossJG , JenkinsRB , MehtaM , et al. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathology2008;18:360-9. ">Cairncross 2006</a>; <a href="./references#CD007104-bbs2-0003" title="IdbaihA , DalmassoC , KouwenhovenM , JeukenJ , CarpentierC , GorliaT , et al. Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951. Journal of Neuro-oncology2011;103:221-30. KouwenhovenMC , GorliaT , KrosJM , IbdaihA , BrandesAA , BrombergJE , et al. Molecular analysis of anaplastic oligodendroglial tumors in a prospective randomized study: a report from EORTC study 26951. Neuro-oncology2009;11:737-46. MauerME , TaphoornMJ , BottomleyA , CoensC , EfficaceF , SansonM , et al. Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group study. Journal of Clinical Oncology2007;25:5731-37. MokhtariK , DucrayF , KrosJM , GorliaT , IdbaihA , TaphoornM , et al. Alpha internexin expression predicts outcome in anaplastic oligodendroglial tumors and may positively impact the efficacy of chemotherapy. Cancer2011;117:3014-26. vanden BenMJ , BrandesAA , TaphoornMJ , KrosJM , KouwenhovenMC , DelattreJY , et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2013;31:344-50. vanden BentMJ , CarpentierAF , BrandesAA , SansonM , TaphoornMJ , BernsenHJ , et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of Clinical Oncology2006;24(18):2715-22. vanden BentMJ , DubbinkHJ , MarieY , BrandesAA , TaphoornMJ , WesselingP , et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research2010;16:1597-604. vanden BentMJ , DubbinkHJ , SansonM , van derLee-HaarlooCR , HegiM , JeukenJW , et al. MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology2009;27:5881-6. vanden BentMJ , GravendeelLA , GorliaT , KrosJM , LapreL , WesselingP , et al. A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research2011;17:7148-55. ">van den Bent 2006</a>). However, these studies were not designed to analyze this biomarker and stratification was done retrospectively. In the NOA‐04, codeletion did not remain prognostic of PFS in multivariate analysis, but was underpowered to do so (<a href="./references#CD007104-bbs2-0002" title="WickW , HartmannC , EngelC , StoffelsM , FelsbergJ , StockhammerF , et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of Clinical Oncology2009;27(35):5874-80. ">NOA‐04 2009</a>). Nevertheless, evidence for the prognostic value of codeletion is growing (<a href="./references#CD007104-bbs2-0016" title="LassmanAB , IwamotoFM , CloughesyTF , AldapeKD , RiveraAL , EichlerAF , et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro-oncology2011;13:649-59.">Lassman 2011</a>; <a href="./references#CD007104-bbs2-0017" title="LiS , YanC , HuangL , QiuX , WangZ , JiangT . Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro-oncology2012;14:109-16.">Li 2012</a>). Furthermore, the RTOG trial found 1p and 19q codeletion to be a predictive factor for OS, and the EORTC trial reported a trend for codeletion to predict response to combined treatment. </p> <p>The value of the IDH‐1 or ‐2 biomarker is gaining in recognition. In the RTOG trial, participants with IDH‐1 or ‐2 mutated tumours benefited from combined chemotherapy and RT, independently of codeletion status. It was found to be both prognostic and predictive for OS. In the EORTC trial, IDH mutation status was shown to be prognostic, and there was a trend towards a predictive value. In the NOA‐04 study, multivariate analysis not only showed correlation between longer time to treatment failure and IDH‐1 mutation, but it was also shown to confer a stronger risk reduction than codeletion, MGMT promoter methylation and AO or AOA histology as compared with AA. The prognostic value of IDH‐1 or ‐2 was also supported by other studies (<a href="./references#CD007104-bbs2-0017" title="LiS , YanC , HuangL , QiuX , WangZ , JiangT . Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro-oncology2012;14:109-16.">Li 2012</a>; <a href="./references#CD007104-bbs2-0027" title="YanH , ParsonsDW , JinG , McLendonR , RasheedBA , YuanW , et al. IDH1 and IDH2 mutations in gliomas. New England Journal of Medicine2009;360:765-73.">Yan 2009</a>). Its potential as a predictive biomarker will nevertheless require to be studied further. </p> <p>There are currently two large international phase 3 trials accruing anaplastic glioma participants and selecting participants according to codeletion status. The CATNON trial will focus on participants without codeletion and will randomize in four different treatment arms involving RT with or without temozolomide at different time points (<a href="./references#CD007104-bbs2-0018" title="NCT00626990. Radiation therapy with or without temozolomide in treating patients with anaplastic glioma. clinicaltrials.gov/ct2/show/NCT00626990 (accessed 13 May 2014).">NCT00626990</a>). The CODEL study (<a href="./references#CD007104-bbs2-0019" title="NCT00887146. Radiation therapy with concomitant and adjuvant temozolomide or radiation therapy with adjuvant PCV or temozolomide alone in treating patients with anaplastic glioma. clinicaltrials.gov/show/NCT00887146 (accessed 13 May 2014).">NCT00887146</a>) will include only participants with codeleted tumours will randomize participants to RT, temozolomide or RT with concurrent and adjuvant temozolomide. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007104-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/media/CDSR/CD007104/urn:x-wiley:14651858:media:CD007104:CD007104-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007104-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007104.pub2/media/CDSR/CD007104/image_n/nCD007104-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/media/CDSR/CD007104/image_t/tCD007104-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full#CD007104-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/media/CDSR/CD007104/image_n/nCD007104-FIG-01.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table data-id="CD007104-tbl-0001"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of the studies</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>RTOG 9402</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>EORTC 26951</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>NOA‐04</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Histology</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AO and AOA with at least 25% oligodendroglial elements</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AO and AOA with at least 25% oligodendroglial elements</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>AO, AOA and AA</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Pathological characteristics</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2 of 5: high cellularity, nuclear polymorphism, mitotic activity, endothelial proliferation and necrosis </p> <p>At least 1 needs to be mitosis or endothelial proliferation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 of 5: high cellularity, mitosis, nuclear abnormalities, endothelial proliferation and necrosis </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3 of 4: high cellularity, mitotic activity, nuclear polymorphism and vascular proliferation</p> <p>No necrosis</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate of codeletion of chromosomes 1p and 19q</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>47.9%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>25.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>40.9%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Number of participants randomly assigned</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>289</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>368</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>274</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Randomization arms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ RT + PCV intensive regimen 4 cycles prior to RT (n = 147)</p> <p>‐ RT alone (n = 142)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ RT + PCV 6 cycles after RT (n = 185)</p> <p>‐ RT alone (n = 183)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ RT first, chemotherapy at recurrence (n = 139)</p> <p>‐ chemotherapy first, RT at recurrence (n = 135)</p> <p>PCV 4 cycles (n = 68)</p> <p>Temozolomide 8 cycles (n = 67)</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Rate of chemotherapy a time of recurrence in RT arms</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>79.0%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>74.5%</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>48%</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Median survival</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 4.6 years for RT plus PCV</p> <p>‐ 4.7 years for RT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 3.5 years for RT plus PCV</p> <p>‐ 2.6 years for RT alone</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐ 6.0 years for RT first</p> <p>‐ 6.9 years for chemotherapy first</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Loss of heterozygosity</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic and predictive for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic for PFS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>MGMT</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>NA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Not prognostic for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic for PFS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>IDH‐1 or ‐2</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic and predictive for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic for OS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Prognostic for PFS</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p><b>Author's clinical conclusion</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>For the subset of participants with 1p/19q codeleted or IDH‐1 or ‐2 mutated AO/AOA, PCV plus RT may be an especially effective treatment </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>PCV plus RT increases both OS and PFS in AO/AOA. Codeleted tumours derive more benefit from adjuvant PCV compared with non‐codeleted tumours </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Initial RT or chemotherapy achieved comparable results in participants with anaplastic gliomas </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>AA: anaplastic astrocytoma; AO: anaplastic oligodendroglioma; AOA: anaplastic oligoastrocytoma; IDH: isocitrate dehydrogenase; MGMT: O<sup>6</sup>‐methylguanine‐DNA methyltransferase; NA: not applicable; OS: overall survival; PCV: procarbazine, lomustine and vincristine; PFS: progression‐free survival; RT: radiotherapy. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Summary of the studies</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007104.pub2/full#CD007104-tbl-0001">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007104.pub2&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007104-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007104-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="ms#CD007104-note-0003">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"/> </img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br/> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007104\x2epub2"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007104\x2epub2"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007104\x2epub2"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007104\x2epub2\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007104\x2epub2"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=dLyXbLct&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007104.pub2&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007104.pub2';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007104.pub2/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007104.pub2/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007104.pub2%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740718707527"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007104.pub2/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740718707531"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007104.pub2/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918dd6e93b7af47a',t:'MTc0MDcxODcwNy4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 